XML 50 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Composition of Certain Financial Statement Captions (Tables)
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Composition of Certain Financial Statement Captions
 
For the years ended December 31,
(In thousands)
2019
 
2018
Accounts receivable, net
 
 
 
Accounts receivable
$
136,551

 
$
145,665

Less: allowance for doubtful accounts
(1,934
)
 
(1,758
)
 
$
134,617

 
$
143,907

Inventories, net
 
 
 
Consumable supplies
$
23,005

 
$
23,264

Finished products
25,142

 
15,259

Work in-process
3,238

 
2,473

Raw materials
4,586

 
4,259

Less: inventory reserve
(2,537
)
 
(2,956
)
 
$
53,434

 
$
42,299

Other current assets and prepaid expenses
 
 
 
Taxes recoverable
$
19,808

 
$
15,708

Other receivables
$
3,262

 
$
2,368

Prepaid supplies
8,147

 
9,693

Prepaid insurance
3,486

 
3,436

Other
15,839

 
3,847

 
$
50,542

 
$
35,052

Property, plant and equipment, net:
 
 
 
Machinery, medical and other equipment
$
165,501

 
$
147,757

Leasehold improvements
33,606

 
34,607

Furniture and fixtures
12,631

 
12,737

Automobiles and aircraft
10,029

 
10,133

Software
13,861

 
13,425

Building
18,462

 
18,554

Land
2,422

 
2,453

Construction in process
7,044

 
16,670

Less: accumulated depreciation
(136,445
)
 
(111,662
)
 
$
127,111

 
$
144,674

Intangible assets, net:
 
 
 
Customer relationships
$
445,408

 
$
446,296

Technologies
296,246

 
340,729

Trade names
49,786

 
50,404

Covenants not to compete
16,318

 
16,322

Licenses
5,766

 
5,766

Product registrations
7,578

 
7,861

Other
6,094

 
5,613

Less: accumulated amortization
(298,234
)
 
(258,539
)
 
$
528,962

 
$
614,452


 
For the years ended December 31,
(In thousands)
2019
 
2018
Accrued expenses:
 
 
 
Contract liabilities
$
19,196

 
$
63,503

Employee benefits
33,671

 
45,621

Commitments and Contingencies
38,635

 
15,327

Clinical trials
8,122

 
10,401

Professional fees
1,333

 
2,952

Finance leases short-term
2,743

 
3,280

Milestone payment
—

 
4,871

Contingent consideration
2,375

 
2,375

Other
58,850

 
55,183

 
$
164,925

 
$
203,513

 
 
 
 
Other long-term liabilities:
 
 
 
Line of credit
$
44,749

 
$
105,198

Contract liabilities
2,571

 
27,566

Contingent consideration
7,308

 
22,162

Finance leases long-term
4,046

 
5,620

Mortgages and other debts payable
3,906

 
4,654

Other
25,224

 
33,768

 
$
87,804

 
$
198,968
Summary of Valuation Allowance
The following table reflects the changes in the allowance for doubtful accounts, provision for inventory reserve and tax valuation allowance accounts:
(In thousands)
Beginning
balance
 
Charged
to
expense
 
Written-off
 
Ending
balance
2019
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
(1,758
)
 
(469
)
 
293

 
$
(1,934
)
Inventory reserve
$
(2,956
)
 
(2,349
)
 
2,768

 
$
(2,537
)
Tax valuation allowance
$
(154,916
)
 
(38,340
)
 
—

 
$
(193,256
)
2018
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
(1,446
)
 
(665
)
 
353

 
$
(1,758
)
Inventory reserve
$
(6,565
)
 
(1,915
)
 
5,524

 
$
(2,956
)
Tax valuation allowance
$
(142,062
)
 
(12,854
)
 
—

 
$
(154,916
)
Schedule of Goodwill
The following table summarizes the changes in Goodwill by reporting unit during the years ended December 31, 2019 and 2018.
 
2019
 
2018
(In thousands)
Balance at January 1
 
Goodwill impairment
 
Foreign exchange and other
 
Balance at December 31st
 
Balance at January 1
 
Goodwill impairment
 
Foreign exchange and other
 
Balance at December 31
Pharmaceuticals
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CURNA
$
4,827

 
$
(4,827
)
 
$
—

 
$
—

 
$
4,827

 
$
—

 
$
—

 
$
4,827

Rayaldee
87,314

 
—

 
(1,709
)
 
85,605

 
91,295

 
—

 
(3,981
)
 
87,314

FineTech
—

 
—

 
—

 
—

 
11,698

 
(11,698
)
 
—

 
—

OPKO Biologics
139,784

 

 
—

 
139,784

 
139,784

 
—

 
—

 
139,784

OPKO Chile
4,614

 

 
(266
)
 
4,348

 
5,203

 
—

 
(589
)
 
4,614

OPKO Health Europe
7,546

 

 
(152
)
 
7,394

 
7,898

 
—

 
(352
)
 
7,546

Transition Therapeutics
3,322

 
(3,421
)
 
99

 
—

 
3,608

 
—

 
(286
)
 
3,322

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostics
 
 
 
 
 
 
 
 

 

 

 

BioReference
434,809

 
—

 
—

 
434,809

 
434,809

 
—

 
—

 
434,809

OPKO Diagnostics
17,977

 
(17,977
)
 
—

 
—

 
17,977

 
—

 
—

 
17,977

 
$
700,193

 
$
(26,225
)
 
$
(2,028
)
 
$
671,940

 
$
717,099

 
$
(11,698
)
 
$
(5,208
)
 
$
700,193